333 related articles for article (PubMed ID: 15679176)
21. 2B-Trans technology: targeted drug delivery across the blood-brain barrier.
Gaillard PJ; de Boer AG
Methods Mol Biol; 2008; 437():161-75. PubMed ID: 18369968
[TBL] [Abstract][Full Text] [Related]
22. Critical role of actin in modulating BBB permeability.
Lai CH; Kuo KH; Leo JM
Brain Res Brain Res Rev; 2005 Dec; 50(1):7-13. PubMed ID: 16291072
[TBL] [Abstract][Full Text] [Related]
23. Drug delivery to the central nervous system: a review.
Misra A; Ganesh S; Shahiwala A; Shah SP
J Pharm Pharm Sci; 2003; 6(2):252-73. PubMed ID: 12935438
[TBL] [Abstract][Full Text] [Related]
24. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
Deeken JF; Löscher W
Clin Cancer Res; 2007 Mar; 13(6):1663-74. PubMed ID: 17363519
[TBL] [Abstract][Full Text] [Related]
25. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
26. The critical component to establish in vitro BBB model: Pericyte.
Lai CH; Kuo KH
Brain Res Brain Res Rev; 2005 Dec; 50(2):258-65. PubMed ID: 16199092
[TBL] [Abstract][Full Text] [Related]
27. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
28. Delivery of peptide and protein drugs over the blood-brain barrier.
Brasnjevic I; Steinbusch HW; Schmitz C; Martinez-Martinez P;
Prog Neurobiol; 2009 Apr; 87(4):212-51. PubMed ID: 19395337
[TBL] [Abstract][Full Text] [Related]
29. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability.
Zhang Y; Li CS; Ye Y; Johnson K; Poe J; Johnson S; Bobrowski W; Garrido R; Madhu C
Drug Metab Dispos; 2006 Nov; 34(11):1935-43. PubMed ID: 16896068
[TBL] [Abstract][Full Text] [Related]
30. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
31. Challenges for blood-brain barrier (BBB) screening.
Jeffrey P; Summerfield SG
Xenobiotica; 2007; 37(10-11):1135-51. PubMed ID: 17968740
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
Steuer H; Jaworski A; Elger B; Kaussmann M; Keldenich J; Schneider H; Stoll D; Schlosshauer B
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1047-53. PubMed ID: 15728564
[TBL] [Abstract][Full Text] [Related]
33. Effects of transcranial ultrasound and intravenous microbubbles on blood brain barrier permeability in a large animal model.
Xie F; Boska MD; Lof J; Uberti MG; Tsutsui JM; Porter TR
Ultrasound Med Biol; 2008 Dec; 34(12):2028-34. PubMed ID: 18692294
[TBL] [Abstract][Full Text] [Related]
34. Chapter 3 - Colloidal systems for CNS drug delivery.
Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
[TBL] [Abstract][Full Text] [Related]
35. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier.
Andrieux K; Couvreur P
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(5):463-74. PubMed ID: 20049811
[TBL] [Abstract][Full Text] [Related]
36. [The blood-brain barrier and drug delivery in the central nervous system].
Loch-Neckel G; Koepp J
Rev Neurol; 2010 Aug; 51(3):165-74. PubMed ID: 20645267
[TBL] [Abstract][Full Text] [Related]
37. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.
Lacombe O; Videau O; Chevillon D; Guyot AC; Contreras C; Blondel S; Nicolas L; Ghettas A; Bénech H; Thevenot E; Pruvost A; Bolze S; Krzaczkowski L; Prévost C; Mabondzo A
Mol Pharm; 2011 Jun; 8(3):651-63. PubMed ID: 21438632
[TBL] [Abstract][Full Text] [Related]
38. Chapter 1 - Drug delivery to the brain using colloidal carriers.
Chang J; Jallouli Y; Barras A; Dupont N; Betbeder D
Prog Brain Res; 2009; 180():2-17. PubMed ID: 20302826
[TBL] [Abstract][Full Text] [Related]
39. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound.
Kinoshita M; McDannold N; Jolesz FA; Hynynen K
Biochem Biophys Res Commun; 2006 Feb; 340(4):1085-90. PubMed ID: 16403441
[TBL] [Abstract][Full Text] [Related]
40. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
